D
espite improvements in patient care and immunosuppressive regimens, allograft rejection remains a formidable risk factor for morbidity and mortality in heart transplant recipients. [1] [2] [3] It is widely accepted that donor-specific HLA antibodies (DSA) are associated with antibody-mediated rejection (AMR) and poor graft survival. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Therefore, implementing a scheme of routine monitoring for DSA after transplantation has the potential to identify patients for early intervention and improve long-term outcomes. To develop an optimal posttransplant immune assessment protocol, it is important to understand the tempo of HLA DSA development after heart transplant and whether or not it differs in patients with a prior history of allosensitization and/or placement of a mechanical circulatory device. Approximately 30% of heart transplant recipients are sensitized to HLA antigens before transplant. 16 Mechanisms of sensitization to HLA are pregnancy, blood transfusion, surgery to implant a homograft, or prior transplant. Heart transplant patients with implanted ventricular assistant devices (VAD) are particularly prone to developing HLA antibodies due to multiple platelet and blood transfusions. 17, 18 Donor-specific HLA antibodies mediate graft damage by binding to target HLA antigens expressed on the endothelium of the allograft and activating complement via the classical pathway. Activation and deposition of various complement components, including C1q, C4b, C4d, C3a, C3d, and C5, contribute to endothelial cell injury and microvascular inflammation during AMR. 6, 10, 11, 19 HLA DSA may also activate and injure endothelial cells via complement independent pathways, by transducing signals that promote endothelial cell migration, proliferation, adhesion molecule expression, and recruitment of leukocytes to the allograft. [20] [21] [22] C4d deposition on the graft endothelium and presence of intravascular activated monocytes are criteria for diagnosis of AMR in cardiac transplantation. 1 The cell-based complement-dependent cytotoxicity test has been in use for over 50 years to detect complement fixing antibodies. However, weaker HLA antibodies can go undetected due to low sensitivity, and nonspecific binding in this assay can result in false positive results. In contrast, the solid phase IgG single-antigen bead (IgG-SAB) test detects HLA antibodies with increased sensitivity and specificity. The IgG-SAB test is a semiqualitative assay that provides a measurement of the strength of IgG HLA antibodies reported as median fluorescence intensity (MFI). Currently, the results of the IgG-SAB test are widely used to aid risk assessment at the time of a deceased donor offer through virtual crossmatches. The IgG-SAB has also being used for the identification of posttransplant DSA in supporting the diagnosis of AMR. 23 However, the IgG-SAB test cannot distinguish between complement fixing noncomplement fixing antibodies that may differ in pathogenicity after solid organ transplantation. 24 Two solid phase assays have been developed that allow for the detection of complement-fixing HLA antibodies. The C1q-SAB test measures the binding of the C1q molecule to the Fc regions of HLA antibody and is a necessary step to initiate the complement cascade. [25] [26] [27] [28] [29] The C3d-SAB assay detects the complement split product of C3d. 30, 31 Donor-specific HLA antibody not present before transplant but develop for the first time after transplantation in response to HLA alloantigen exposure are considered de novo HLA DSA (dnDSA). The identification of dnDSA can be difficult without a complete history of pretransplant antibody monitoring or when the HLA antibody falls below the detection threshold of the IgG-SAB test. 15 Therefore, early identification of posttransplant HLA DSA, in particular between 2 weeks and 3 months, can reflect either a memory response to prior alloantigen exposure or can be truly de novo. 32 Because we are unable to distinguish between true dnDSA and DSA that are developed early post transplant in an amnestic response, we adopted the use of the term newly detected DSA (ndDSA). 15 Posttransplant ndDSA are defined as any DSA that were not identified in pretransplant tests but are identified any time after transplantation. The goal of this study was to determine the association of preformed and ndDSA with AMR and patient survival. The second goal of the study was to evaluate the clinical significance of complement activating antibodies using C3d-SAB in heart transplant recipients.
MATERIALS AND METHODS

Study Population
The study included 128 adult and 48 pediatric heart transplant patients transplanted between 2010 and 2013 at University of California, Los Angeles. Forty-seven patients received a VAD as bridge to transplantation (BTT). Demographic information was collected by reviewing the patient's medical record during the period of 2014-2016. Fifty patients received induction therapy in this cohort. All patients received triple-drug immunosuppression (tacrolimus, mycophenolate mofetil, and corticosteroids). Research approval for this study was granted by the University of California, Los Angeles Institutional Review Board (IRB 01-08-015-21).
Diagnosis of Rejection and Transplant Coronary Artery Disease
Adult cardiac transplant recipients underwent routine surveillance endomyocardial biopsies weekly in the first month, biweekly in month 2, and at months 3, 4, 5, 6, 9, and 12. Additional biopsies were performed when there was clinical suspicion of rejection. Protocol biopsies of pediatric patients were obtained at weeks 1, 3, and 6, months 3 and 6, and annually thereafter unless clinical concerns for rejection arose. For patients younger than 1 year, the first biopsy occurred no earlier than 3 months posttransplant. A total of 1465 endomyocardial biopsies were obtained from 176 patients. Acute cellular rejection (ACR) and AMR were diagnosed according to International Society for Heart and Lung Transplantation criteria. 33 Coronary angiography was performed annually posttransplant. A diagnosis of transplant coronary artery disease (TCAD) was made when new luminal stenosis 30% or greater or significant distal pruning of the coronary arteries was identified in comparison with baseline angiogram.
HLA Typing and Evaluation of HLA Antibodies
HLA typing of patients and donors was performed for HLA-A, -B, -C, -DRB1, and -DQB1 loci using LABType SSO (One Lambda, Canoga Park, CA). HLA typing of the -DQA1 and -DPA1, -DPB1 loci were performed if recipients displayed HLA antibodies to these antigens.
Undiluted pretransplant and posttransplant sera samples were treated with DTT and tested for HLA antibodies using the IgG-SAB Assay from both One Lambda (Canoga Park, CA) and Immucor (Stamford, CT) as previously described. 34 The results were highly concordant between the companies. Antibodies were considered positive if the MFI is greater than 1000 for HLA-A, -B, -DR, -DQ and greater than 2000 was used for HLA-C and -DP. In correlation with our clinical practice, a higher cutoff for HLA-C and -DP is used because there is a greater amount of HLA-C and -DP antigen bound to the Luminex IgG-SAB beads. Routine posttransplant HLA antibody testing was performed at weeks 1, 2, 3, 4, 6, at months 2, 3, 4, 5, 6, 8, 10, 12, and quarterly thereafter and when clinically indicated. Pretransplant antibody status was based on the presence (preformed DSA+) or absence (DSA−) of DSA in the pretransplant sample closest to day of transplantation. Posttransplant ndDSA were defined as posttransplant DSA identified any time after transplantation when the pretransplant tests were DSA negative.
C3d-SAB Test
Undiluted sera positive for IgG HLA antibodies were tested for C3d binding antibodies by using C3d-SAB kit according to the manufacturer's protocol (Immucor, Stamford, CT). Briefly, 40 μL of luminex single antigen bead mix were incubated with 10 μL of serum for 30 minutes at room temperature (RT) in the dark on a rotating platform. After incubation, 30 μL of complement containing serum was added to each well and incubated for another 30 minutes at RT. After 4 washes, 50 μL of C3d conjugate was added to each well and incubated for 30 minutes at RT. After the final wash, 200 μL of wash buffer was added and data was collected using the Luminex platform. Antibodies with MFI greater than 1000 were considered positive. The immunodominant DSA was defined as the DSA with the highest normalized MFI value.
Statistical Analysis
Contingency tables were analyzed for differences in proportions among categorical variables between recipients with and without rejection using Fisher exact test. Differences in mean values of continuous variables were analyzed via Wilcoxon rank-sum test. Logistic regression models were used to evaluate odds ratio (OR). Statistical significance was defined as a P value less than 0.05, allowing for multiple comparisons of main variables via Bonferroni procedure. All P values were 2-sided, and all estimates were done via the STATA statistical software (StataCorp. 2003. Stata Statistical Software. College Station, TX: Stata Corporation). Actuarial graft survival and freedom from TCAD was estimated using Kaplan-Meier analysis, and statistical differences were calculated with the log-rank statistic.
RESULTS
One hundred seventy-six cardiac transplant recipients comprised 48 children and 128 adults were prospectively monitored for the development of HLA DSA after transplantation ( Table 1 ). The median follow-up time was 17.9 months for patients without AMR and 15.7 for patients with AMR (P = 0.63). Thirty-four (19.3%) of 176 patients were diagnosed with AMR. Four of 34 AMR+ patients had concomitant ACR ≥ 2R. Six patients had an isolated ACR episode ≥2R. Statistical analysis showed no association between diagnosis of AMR and recipient age, sex, race, or number of HLA mismatches between recipient and donor. Interestingly, patients that developed AMR were more likely to be recipients of combined heart/liver or heart/kidney transplants (P < 0.01). Seventeen patients received combined heart/kidney transplant, 7 of 17 had diagnoses of AMR in the transplanted hearts, 2 of 17 had concomitant AMR in the kidney allografts, AMR was never diagnosed in the kidney alone. Forty-seven patients had VAD placed as BTT. Antibody-mediated rejection was diagnosed in 14 (29.8%) of 47 VAD+ patients compared with 20 (15.5%) 129 VAD− patients, indicating the placement of VAD is a risk factor for AMR (P < 0.05, Table 1 ).
Preformed HLA DSA and AMR Twenty-two of 176 patients were transplanted with preformed DSA (Table 2A) . Preformed DSA were targeted to either HLA class I (n = 10; 6 against A; 2 against B; 1 against A + C; 1 against A + B), class II (n = 9; 4 against DR; 4 against DQ; 1 against DR + DQ), or both class I/II antigens (n = 3; 1 against A + DQ; 1 against A + DR + DQ; 1 
Patient demographics
AMR neg AMR pos
Adult age (mean ± SD) (n = 128), y 52.6 ± 12.3 (n = 101) 48.6 ± 13.6 (n = 27) 0.13 Pediatric age (mean ± SD) (n = 48), y 8.3 ± 7.0 (n = 41) 12.9 ± 6.5 (n = 7) 0. .01 Heart/kidney (n = 17) 10 7 Heart/liver (n = 3) 1 2 HLA-A mismatches (mean ± SD)
1.6 ± 0.5 1.7 ± 0.5 0.68 HLA-B mismatches (mean ± SD)
1.8 ± 0.4 1.9 ± 0.5 0.16 HLA-DR mismatches (mean ± SD) 1.5 ± 0.6 1.6 ± 0.6 0.49 HLA-DQ mismatches (mean ± SD)
1.4 ± 0.6 1. Table 2B ). Presensitization to donor HLA was associated with AMR in VAD+ patients.
ndDSA and AMR
All patients waiting for heart transplant were monitored by routine pretransplant solid phase antibody testing either biannually, quarterly or monthly according to the patients' waitlist status and sensitization history. Routine posttransplant immune assessment provided an opportunity to characterize the evolution of ndDSA in primary heart allograft recipients. In the 154 patients transplanted without preformed DSA, 43 patients developed ndDSA. The 3-year cumulative incidence of ndDSA development was 28% (Table 2A) . Majority of the patients made ndDSA to class II (n = 24; 14 of them made ndDSA to DQ; 5 to DR; 4 to DR + DQ; 1 to DP), 6 to class I (2 to A; 2 to B; 2 to C), and 13 to both class I/II (10 of 13 patients had ndDSA to DQ in addition to DSA of other specificities). Development of ndDSA was significantly associated with AMR. Among the ndDSA producers, 15 (35%) of 43 patients experienced AMR compared with 11 (9.9%) 111 ndDSA− patients (P < 0.001, Table 2A ). Of the 47 VAD+ patients, 9 patients had preformed DSA, 38 patients had no preformed DSA. Seven of 9 VAD+ patients with preformed DSA had AMR compared with 7 of 31 VAD+ patients without preformed DSA (P < 0.01, Table 2B ). Of the 43 patients that developed ndDSA, 13 of 43 patients had VAD before transplant, 6 (46%) of 13 VAD+ patients experienced AMR compared with 9 (30%) 30 VAD− patients (P = 0.49, Table 2B ). The cumulative incidence ndDSA was illustrated in Figure 1 . There was no significant difference in the incidence of ndDSA in pediatric and adult transplant recipients ( Figure 1A , P= 0.72). The time to identification of the first ndDSA was evaluated in the 43 ndDSA+ patients and in 13 of the 22 patients transplanted with preformed DSA that developed ndDSA to additional HLA specificities. The median time of ndDSA development in patients transplanted with preformed DSA was 1.6 months, much earlier than sensitized patients transplanted with thirdparty antibodies (sensitized DSA−, 7.7 months) and nonsensitized patients (9.4 months; P < 0.05, Figure 1B) . In patients transplanted with preformed DSA, 5 of 13 developed ndDSA within 1 month, and 11 of 13 developed ndDSA within 6 months of transplant. However, 11 of 23 nonsensitized patients and 8 of 20 sensitized DSA− patients developed ndDSAwithin 6 months, respectively, indicating the importance of early posttransplant monitoring in all groups of patients. The cumulative incidence of ndDSA stratified by patient sensitization was shown in Figure 1C . Patients with preformed DSA developed ndDSA to additional mismatched donor HLA antigens at a faster rate than sensitized patients without HLA DSA or nonsensitized patients (P < 0.01). Analysis of the cumulative incidence of ndDSA showed that there was no significant difference in patients who received induction therapy compared with patients without induction therapy (P = 0.65, Figure 1D ).
Correlation of C3d + DSA With AMR
We next determined if complement-activating DSA detected by the C3d-SAB assay correlated with AMR. The C3d-SAB test was performed on the 22 patients transplanted with preformed DSA and 43 patients who developed posttransplant ndDSA. Univariate logistic regression analysis was used to evaluate odds of developing AMR in patients with and without complement activating DSA in comparison to DSA− patients. DSA+ C3d− patients had 2.8 OR for higher risk of developing AMR compared to DSA negative patients (P < 0.05; Table 3 ). The risk of AMR dramatically increased 33 times for C3d+ DSA patients compared to patients without DSA (P < 0.001).
To determine if C3d+ DSA correlated with C4d deposition in the graft, we evaluated 35 DSA+ patients who had DSA 7 days before and up to 2 days after their endomyocardial biopsies. Biopsies were categorized into C4d+ AMR+ (n = 10), C4d−AMR+ (n = 6) and C4d−AMR− (n = 19) groups. Thirteen (37%) of 35 patients developed C3d + DSA. Among them, 7 were diagnosed with C4d+ AMR+, 4 had C4d− AMR+, and 2 had no AMR (Table 4 ). Although in the 22 patients with C3d− DSA, only 3 had C4d+ deposition, indicating that the presence of C3d+ DSA was significantly associated with C4d deposition in AMR+ biopsies (P < 0.01).
To further correlate C3d+ DSA to AMR, the immunodominant MFI of IgG+ DSA was plotted against C3d DSA positivity in AMR+ and AMR− patients (Figure 2) . Patients with C3d+ DSA had higher IgG+ DSA MFI (10383 ± 1497) compared with patients with C3d-DSA (3,474 ± 537, P < 0.01). Notably, when the MFIs of the IgG+ DSA were compared between the 2 groups, there was a wider range of MFIs in the C3d+ DSA group compared with the C3d− DSA group. Furthermore, 5 AMR+ patients with IgG+ DSA < 10000 MFI were C3d+ and experienced AMR, suggesting that the C3d− SAB assay may be a useful tool to identify patients at risk of AMR, even in the context of weak to moderate IgG+ DSA.
Correlation of DSA With TCAD
Among 132 patients who had a follow-up greater than 1 year, 9 (36%) of 25 patients with AMR developed TCAD compared with 17 (15.9%) of 107 patients without AMR (P < 0.05, Table 5 ). The TCAD incidence rate was 2.3 cases per month per 100 cases in patients with AMR compared with 1.0 case per month per 100 cases in patients without AMR (P < 0.05, Table 5 ).
HLA DSA and Graft Survival
Patients with AMR experienced a trend toward more graft failure than patients without AMR. The 3-year TCAD-free survival rate was 81.4% in patients without AMR and 58.9% in patients with AMR (P = 0.09, Figure 3A) . To study the long-term effect of preformed DSA and ndDSA on graft survival, preformed DSA and ndDSA were correlated with TCAD in patients who had more than 1 year of follow-up.
Patients with ndDSA had a 68% TCAD-free survival at 3 years posttransplant compared with 82% for patients with preformed DSA and 84% for patients without DSA. However, there was no significant difference in TCAD-free survival comparing patients with ndDSA, preformed DSA, and no DSA (P = 0.31, Figure 3B ).
DISCUSSION
The goal of this study was to determine the evolution of posttransplant development of DSA and characterize the clinical relevance of complement activating DSA in heart allograft recipients. The main findings of this study showed both pretransplant and posttransplant DSA were associated with higher incidence of AMR in heart transplant recipients. In particular, VAD+ patients transplanted with preformed HLA DSA had a higher risk of AMR. Notably, the median time of ndDSA development in patients transplanted with preformed DSA was 1.6 months; significantly earlier than sensitized patients transplanted without DSA. However, regardless of pretransplant sensitization status, nearly half of the heart transplant recipients developed DSA by 6 months posttransplant. We demonstrated that patients with preformed DSA developed ndDSA to additional HLA specificities at a much faster rate than sensitized patients without HLA DSA or nonsensitized patients suggesting that donor-specific memory B cells were likely present in these sensitized recipients at the time of transplantation. This finding was consistent with studies by Han et al that investigated the presence of memory B cells in sensitized allograft recipients. They found that HLA antibody-producing B cells detected in sensitized individuals were mainly comprised of memory B cells. 35 This supports the premise that alloreactive memory B cells exhibit recall responses with faster kinetics compared with naive B cells. 36 Patients with C3d+ DSA had a significantly higher risk of AMR compared with patients with C3d− DSA. A significantly higher number of patients with AMR also developed TCAD compared with patients without AMR. There was no significant difference found between the pediatric and adult cohorts in ndDSA development, the incidence of AMR and patient survival, probably due to the relatively small population of the pediatric cohort.
In our previous report, dnDSAwas found in 20% of the patients and the development of dnDSA was strongly linked with AMR and TCAD in heart transplant recipients. 5 Similarly, in an adult cardiac transplant study, dnDSA was reported in 23.4% of patients and was significantly associated with poor patient survival. 9 A slightly higher incidence of dnDSA was reported in 2 pediatric cardiac transplant cohorts. 13, 37 In both reports,~40% of the patients developed dnDSA and the development of dnDSA was significantly associated with higher incidence of TCAD and poor graft survival. Patients who received VAD as BTT are considered high risk for developing HLA DSA in part due to frequent blood and platelet transfusions. 17 In our cohort, VAD+ patients, particularly those transplanted with preformed DSA, had significantly higher risk of AMR compared to VAD− patients. Ko et al 38 recently reported among 113 VAD+ patients, 25% of them became sensitized after VAD implantation. These patients had a higher risk of ACR and AMR compared to VAD− patients.
The incidence of dnDSA in heart transplant patients is similar to what is reported for kidney transplantation. 30, [39] [40] [41] In an adult kidney transplant study, Everly et al 40 reported a 5-year accumulative incidence of dnDSA is 20% in a cohort of 189 nonsensitized primary kidney transplant recipients. The authors reported the annual incidence of DSA is highest in the first year posttransplant (11%) accounting for more than 50% of the patients who developed dnDSA. Similarly, Wiebe et al 41 studied 315 consecutive renal transplants without preformed HLA DSA. They showed that 47 (15%) 315 patients developed dnDSA and demonstrated that the 10-year graft survival for patients with dnDSA was significantly lower than patients without DSA (59% vs 96%). The time between the development of DSA and graft loss provides an opportunity for clinical interventions. Walsh et al 42 showed that early therapeutic intervention and rapid reversal of the rejection is associated with improved graft survival compared with late intervention that leads to refractory rejection and irreversible kidney damage.
HLA DSA-induced complement activation not only damages the allograft as an effector system but also promotes the adaptive immune responses. [43] [44] [45] [46] We demonstrated C3d+ DSA was strongly correlated with C4d deposition in endomyocardial biopsies, suggesting C3d+ DSA is more pathogenic compared to C3d− DSA. We found that patients with C3d+ DSA had 33 times higher risk of developing AMR compared with DSA− patients, and 2.8 times higher risk of developing AMR compared with patients with C3d-DSA. Currently, there are 2 solid phase assays to detect complement-fixing HLA antibodies, the C1q-SAB [24] [25] [26] 29, 47 and the C3d-SAB assays. 30, 31 The C1q-SAB test detects the initial binding of the C1q molecule to the Fc regions of HLA antibody. The C3d-SAB assay measures the complement activation product C3b. Recently, Comoli et al 30 reported that C3d+ DSAs were better predictors for AMR and graft loss as compared with C1q+ DSA test in a pediatric kidney transplant cohort. 30 Sicard et al 31 showed that patients with C3d+ DSA had worse estimated glomerular filtration rate and increased risk of AMR and allograft loss in an adult kidney transplant. These data suggest that the C3d− SAB test is useful for identifying patients at higher risk of graft rejection and may benefit from therapeutic intervention with complement inhibitors such as such as the C5 inhibitor (eg, Eculizumab) and C1 inhibitors. 48 Publications on complement fixing DSA in heart transplant patients are small and limited. A study of 18 pediatric heart transplant recipients showed that C1q + DSA had better predictive value for AMR early posttransplant compared with IgG-SAB. 26 Similarly, Zeevi et al 28 reported persistent C1q+ DSA was associated with early clinical AMR in 15 cardiac transplant recipients.
One limitation of the solid phase C3d− SAB assays is that these tests are unable to detect the synergistic effect of multiple DSA as measured by cell-based assays. In addition, the production of HLA antibodies is dynamic; noncomplement fixing antibodies can become complement-fixing antibodies or vice versa. 26 Therefore, although these early C3d-SAB studies are promising, clinical usage of the test needs to be further evaluated.
In conclusion, patients with both preformed and posttransplant ndDSA had significantly higher incidence of AMR and relatively lower graft survival compared with patients without DSA. Patients who had complement-activating DSA were likely to develop C4d+ AMR and earlier graft failure compared to patients with noncomplement fixing antibodies. These results suggest routine posttransplant monitoring by IgG-SAB and C3d− SAB testing may be beneficial for identifying patients at risk of rejection and patients that may benefit from specific therapeutic intervention targeting the complement pathway.
